Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
4,325
datasets available to search
ShareScore release 0.9.0
Dataset results
4,325 results for “real”
Data for "Electro-aging model development of nickel-manganese-cobalt lithium-ion technology validated with light and heavy-duty real-life profiles"
Open the record for dataset details and reuse information.
IMU-based real-time shape estimation of tensegrity structures
<p>IMU-based real-time shape estimation of tensegrity structures</p>
Real Time Identity Processes data
<p>Datasets for the Special Issue "Real-Time Identity Processes" in the journal "Identity : a journal for theory and research". These datas were use for Spearman's rho correlations and Linear Mixed Models.</p>
Adjunctive vortioxetine for SSRI-resistant major depressive disorder: a ''real-world'' chart review study
<p>Adjunctive vortioxetine for SSRI-resistant major<br> depressive disorder: a ‘‘real-world’’ chart review study</p> <p>Objective: Selective serotonin reuptake inhibitors (SSRIs) are the cornerstone of treatment of major<br> depressive disorder (MDD). However, non-response is common, often necessitating combination<br> strategies. The present study assessed the efficacy of vortioxetine as an add-on therapy in patients<br> with SSRI-resistant MDD.<br> Methods: The charts of 36 adult outpatients with DSM-IV-TR MDD who had not achieved a response<br> after at least 8 weeks of treatment with an SSRI were reviewed retrospectively. Subjects were treated<br> with vortioxetine (5-20 mg/day) for 8 weeks added to the current SSRI. The main outcome measures<br> were change from baseline in total Hamilton Scale for Depression (HAM-D) score and the rate of<br> response (a 50% or greater reduction in HAM-D score and a Clinical Global Impression - Improvement<br> module [CGI-I] score of 1 or 2 at endpoint). HAM-D scores p 7 were considered as remission.<br> Additional outcome measures included the Snaith-Hamilton Pleasure Scale (SHAPS) and the Scale<br> for Suicide Ideation (SSI).<br> Results: 32 patients completed the 8 weeks of treatment. At 8 weeks, a significant reduction in HAM-D<br> score was observed (p p 0.001), with response obtained by 41.7% and remission by 33.3% of<br> patients. Significant reductions in SHAPS and SSI were also observed (p p 0.001 for both scales).<br> Conclusions: Adjunctive vortioxetine may be useful and well-tolerated in stage I treatment-resistant<br> depression. However, the limitations of this study (such as small sample size, absence of<br> randomization and control group, retrospective design, etc.) must be considered.</p>
Alexithymia, resilience, somatic sensations and their relationships with suicide ideation in drug naïve patients with first-episode major depression: An exploratory study in the "real world" everyday clinical practice
<p>Alexithymia, resilience, somatic sensations and their<br> relationships with suicide ideation in drug naïve patients<br> with first-episode major depression: An exploratory study<br> in the “real world” everyday clinical practice</p> <p> </p> <p>Aim: The present study is aimed at revaluating alexithymia, somatic sensations, resilience<br> and their relationships with suicide ideation in drug naïve adult outpatients suffering<br> from first episode major depression (MD).<br> Methods: Data of 103 adult outpatients (49 men, 56 women) with a diagnostic and<br> statistical manual of mental disorders, 4th edition, text revision (DSM-IV-TR) diagnosis<br> of MD were analysed. Alexithymia was measured using the 20-item Toronto<br> Alexithymia Scale (TAS-20) and resilience with the 25 items Connor-Davidson Resilience<br> Scale (CD-RISC) whereas depression was evaluated using the 17-item Hamilton<br> Depression Rating Scale, somatic sensations with the Body Sensations Questionnaire<br> and suicide ideation with Scale of Suicide Ideation (SSI).</p> <p>Results: Gender comparisons between all demographic and clinical variables showed<br> no significant differences in all variables. Subjects who were found positive for<br> alexithymia showed higher scores on all clinical variables controlling for age, gender<br> and duration of the current episode. In a linear regression model, lower scores on<br> CD-RISC and Difficulty in Identifying Feelings dimension of TAS-20 were significantly<br> predictive of higher scores on SSI.<br> Conclusions: Alexithymia and low resilience were significant predictors of increased<br> suicide ideation in a first MD episode. However, study limitations must be considered<br> and future research needs are being discussed.</p>
Psychopharmacological treatment in borderline personality disorder: A pilot observational study in a real-world setting
<p>Psychopharmacological treatment in borderline personality disorder: A<br> pilot observational study in a real-world setting</p> <p>Psychotherapy is the cornerstone of treatment for borderline personality disorder (BPD) while pharmacotherapy<br> should be considered only as an adjunctive intervention. In clinical practice, however, most of BPD patients only<br> receive medication. The aim of the study is to first describe pharmacological treatment in BPD patients in Italy<br> and secondly to evaluate if comorbidity or illness severity are associated with the prescription of different class<br> compounds.<br> Data on pharmacological treatment and clinical evaluation of 75 BPD patients were collected in 5 clinical<br> settings. The association between comorbidity and medication was assessed. Moreover, we evaluated the association<br> between pharmacotherapy and severity, defined by a cluster analysis aimed at detecting different groups<br> of patients.<br> Most of the participants (82.7%) were characterized by polypharmacy, with a mean of 2.4 medications per<br> person. Interestingly, the prescription didn’t seem to depend on/be based on the severity of the disorder and was<br> only partially determined by the presence of comorbidity.<br> In conclusion, our findings are similar to what described in other clinical studies, supporting the idea that<br> medication management for BPD is only partially coherent with international guidelines. This pilot study confirms<br> the need for more rigorous studies to gain greater understanding of this topic and diminish the gap between<br> guidelines and the real clinical world.</p>
Alexithymia, suicide ideation, affective temperaments and homocysteine levels in drug naïve patients with post-traumatic stress disorder: an exploratory study in the everyday 'real world' clinical practice
<p>Alexithymia, suicide ideation, affective<br> temperaments and homocysteine levels in drug<br> naïve patients with post-traumatic stress disorder:<br> an exploratory study in the everyday ‘real world’<br> clinical practice</p> <p> </p> <p>Objective: The present exploratory study aimed to investigate relationships between alexithymia, suicide<br> ideation, affective temperaments and homocysteine levels among drug-naïve adult outpatients with Post-<br> Traumatic Stress Disorder (PTSD) in an everyday ‘real world’ clinical setting.<br> Method: Sixty-four adult outpatients with PTSD were evaluated using the Davidson Trauma Scale (DTS),<br> the Toronto Alexithymia Scale (TAS–20), the Scale of Suicide Ideation (SSI), the Temperament Evaluation<br> of the Memphis, Pisa, Paris and San Diego-Autoquestionnaire. As well, homocysteine levels were<br> measured.<br> Results: Alexithymic subjects showed higher values on all scales but not homocysteine levels. Partial correlations<br> showed that almost all studied variables were correlated with each other, except homocysteine<br> levels. Regression analysis showed that higher disorder severity as measured by DTS and TAS-20<br> ‘Difficulty in Identifying Feelings’ dimension was associated with higher SSI scores.<br> Conclusions: In conclusion, alexithymic PTSD outpatients may be characterised by higher disorder severity<br> and difficulty in identifying feelings that may be linked to increased suicide ideation, regardless of<br> affective temperaments or homocysteine levels. Homocysteine levels were not related to any studied variable.<br> However, study limitations are discussed and must be considered.</p>
Disability and mortality in a cohort of MS patients: how the real-world scenario is changed
<p>Demographical (sex and age) and clinical findings (functional system involved at MS onset, MS type, MS disability evaluated via EDSS scale, time to MS progression and use of disease modifying treatment) collected in a cohort of 86 patients with MS and with first hospitalization at IRCCS Mondino, Pavia (italy) in 2005-2006 and followed until 2018. </p>
Dataset related to article "Apremilast for the treatment of palmo-plantar non-pustular psoriasis: A real-life single-center retrospective study"
<p>This record contains raw data related to article “Apremilast for the treatment of palmo-plantar non-pustular psoriasis: A real-life single-center retrospective study"</p> <p>Palmoplantar psoriasis (PP) is a type of psoriasis that involves the skin of the palms and soles and can present as hyperkeratotic, similar to the vulgaris psoriasis of the body. Apremilast, as an oral inhibitor of phosphodiesterase 4 (PDE4), is currently approved for the treatment of psoriatic arthritis and for moderate-to-severe psoriasis in adult patients who have not responded or have contraindications or do not tolerate other systemic treatments. We evaluated the efficacy and safety of apremilast in the treatment of non-pustular palmo-plantar psoriasis in a cohort of 12 patients. We found a clinical response of clear/almost clear palmoplantar psoriasis (PPPGA score 0/1) in 83.33% of our patients, at week 16. No significant safety issues were reported and none of our patients had to discontinue the drug.</p> <p> </p> <p> </p>
Dataset related to the article "Safety and Efficacy of Cryoballoon Ablation of Atrial Fibrillation in relation to the Patients' Age: Results from a Large Real-World Multicenter Observational Project"
<p>This record contains raw data related to the article "Safety and Efficacy of Cryoballoon Ablation of Atrial Fibrillation in relation to the Patients' Age: Results from a Large Real-World Multicenter Observational Project"</p> <p> </p> <p><em><strong>Abstract</strong></em></p> <p><strong>Background: </strong>The real-world efficacy and safety of atrial fibrillation (AF) ablation in particularly young and elderly patients are still under debate. The aim of the analysis was to investigate the effect of age on the efficacy and safety of cryoballoon ablation (CBA).</p> <p><strong>Methods: </strong>2,534 patients underwent pulmonary vein isolation (PVI) by way of CBA for paroxysmal or persistent drug-resistant and symptomatic AF. The population was divided into age quartiles for evaluation, including (1) <53 years, (2) ≥53 and <61 years, (3) ≥61 and <67 years, and (4) ≥67 years. Furthermore, outcomes were analyzed in patients <41 years, ≥41 and ≤74, and >74 years old. Procedural data and complications were collected, and atrial fibrillation recurrences were evaluated during follow-up.</p> <p><strong>Results: </strong>Procedural-related complications (4.1%) were similar in the four subgroups according to age. At the 12-month follow-up, freedom from AF recurrence was 79.2%, 77.4%, 76.8%, and 75.2% (<em>p</em>=0.21), respectively (with increasing age). At 24-month follow-up, similar incidences of AF recurrence were observed in the four subgroups. When the sample was arbitrarily divided into the three age groups, a higher rate of recurrence was observed in older patients with regard to long-term follow-up (freedom from AF recurrence was 71.8% and 40.9%, respectively, at 12 and 24-month follow-up). In the univariate and multivariate analysis, age did not result in a significant predictor of AF recurrence during follow-up; however, a trend toward higher AF recurrences rates in patients ≥67 years was observed.</p> <p><strong>Conclusion: </strong>The data demonstrated a high degree of safety during CBA across all patient ages. Procedural performance and complications were similar between different ages; AF recurrences seem to be more frequent in patients over 74 years.</p>
Dataset related to the article "First-line therapy: insights from a real-world analysis of cryoablation in patients with atrial fibrillation"
<p>This record contains raw data related to the article "First-line therapy: insights from a real-world analysis of cryoablation in patients with atrial fibrillation" </p> <p> </p> <p><em><strong>Abstract</strong></em></p> <p><strong>Aims: </strong>Pulmonary vein isolation (PVI) using cryoballoon ablation (CBA) is mainly reserved for patients with drug-refractory or drug-intolerant symptomatic atrial fibrillation. We evaluated a large cohort of patients treated in a real-world setting and examined the safety and efficacy profile of CBA when applied as a first-line treatment for atrial fibrillation.</p> <p><strong>Methods: </strong>In total, 249 patients (23% women; 56 ± 13 years; mean left atrial diameter 41 ± 7 mm; 73.5% paroxysmal atrial fibrillation; and 26.5% persistent atrial fibrillation) underwent an index PVI by CBA. Data were collected prospectively in the framework of the 1STOP ClinicalService project, involving 26 Italian cardiology centers.</p> <p><strong>Results: </strong>Median procedure and fluoroscopy times were 90.0 and 21.0 min, respectively. Acute procedural success was 99.8%. Acute/periprocedural complications were observed in seven patients (2.8%), including: four transient diaphragmatic paralyses, one pericardial effusion (not requiring any intervention), one transient ischemic attack, and one minor vascular complication. The Kaplan--Meier freedom from atrial fibrillation recurrence was 86.3% at 12 months and 76% at 24 months. Seventeen patients (6.8%) had a repeat catheter ablation procedure during the follow-up period. At last follow-up, 10% of patients were on an anticoagulation therapy, whereas 6.8% were on an antiarrhythmic drug.</p> <p><strong>Conclusion: </strong>In our multicenter real-world experience, PVI by CBA in a first-line atrial fibrillation patient population was well tolerated, effective, and promising. CBA with a PVI strategy can be used to treat patients with paroxysmal and persistent atrial fibrillation with good acute procedural success, short procedure times, and acceptable safety.</p> <p><strong>Clinical trial registration: </strong>clinicaltrials.gov (<a href="http://clinicaltrials.gov/show/NCT01007474">NCT01007474</a>).</p> <p> </p>
RadarTSR real data sets
<p>Glass spectra and NIR spectra data sets</p>
Dataset for: Skilful real-time seasonal forecasts of the dry Northern European Summer 2018
<p>Data required to regenerate any of the figures in GRL publication "Skilful real-time seasonal forecasts of the dry Northern European Summer 2018".</p>
A Real-time PCR assay for rapid identification of Helicoverpa armigera (Lepidoptera: Noctuidae) from closely related species
<p>The bollworm, <em>Helicoverpa armigera</em> is one of the most important agricultural pests in the world. Diagnosis of this species morphologically is difficult from the similar species <em>H. assulta</em>, <em>H. punctigera and H. zea </em>as the adults are identified based on genitalia morphology and larval identification is limited due to shared morphological characters. To provide an accurate diagnosis of New Zealand border interceptions we have developed and validated a real-time PCR assay to identify <em>H. armigera </em>from commonly occurring exotic <em>Helicoverpa</em> species, <em>H. assulta</em> and <em>H. zea</em>. The newly designed primers and probe were optimised, and the assay demonstrated its specificity to <em>H. armigera</em> with no false positives observed in the non-target species tested in this study. The specificity of the assay was tested against 64 samples of Lepidoptera from 14 countries including 48 <em>Helicoverpa </em>samples. The sensitivity of the assay showed it can detect up to 1 copy /µL of the DNA fragment. Therefore, this assay can be used for rapid detection of <em>H. armigera</em>, which is imperative in quarantine application to determine the presence of exotic species regardless of its life stage.</p>
Chest x-ray in the COVID-19 pandemic: Radiologists real-world reader performance.
<p>Dataset from the article Cozzi A, Schiaffino S, Arpaia F, Della Pepa G, Tritella S, Bertolotti P, Menicagli L, Monaco CG, Carbonaro LA, Spairani R, Babaei Paskeh B, Sardanelli F. Chest x-ray in the COVID-19 pandemic: Radiologists' real-world reader performance. Eur J Radiol. 2020 Nov;132:109272. doi: 10.1016/j.ejrad.2020.109272. Epub 2020 Sep 10. PMID: 32971326; PMCID: PMC7481070.</p> <p><strong>Abstract</strong></p> <p><strong>Purpose: </strong>To report real-world diagnostic performance of chest x-ray (CXR) readings during the COVID-19 pandemic.</p> <p><strong>Methods: </strong>In this retrospective observational study we enrolled all patients presenting to the emergency department of a Milan-based university hospital from February 24th to April 8th 2020 who underwent nasopharyngeal swab for reverse transcriptase-polymerase chain reaction (RT-PCR) and anteroposterior bedside CXR within 12 h. A composite reference standard combining RT-PCR results with phone-call-based anamnesis was obtained. Radiologists were grouped by CXR reading experience (Group-1, >10 years; Group-2, <10 years), diagnostic performance indexes were calculated for each radiologist and for the two groups.</p> <p><strong>Results: </strong>Group-1 read 435 CXRs (77.0 % disease prevalence): sensitivity was 89.0 %, specificity 66.0 %, accuracy 83.7 %. Group-2 read 100 CXRs (73.0 % prevalence): sensitivity was 89.0 %, specificity 40.7 %, accuracy 76.0 %. During the first half of the outbreak (195 CXRs, 66.7 % disease prevalence), overall sensitivity was 80.8 %, specificity 67.7 %, accuracy 76.4 %, Group-1 sensitivity being similar to Group-2 (80.6 % versus 81.5 %, respectively) but higher specificity (74.0 % versus 46.7 %) and accuracy (78.4 % versus 69.0 %). During the second half (340 CXRs, 81.8 % prevalence), overall sensitivity increased to 92.8 %, specificity dropped to 53.2 %, accuracy increased to 85.6 %, this pattern mirrored in both groups, with decreased specificity (Group-1, 58.0 %; Group-2, 33.3 %) but increased sensitivity (92.7 % and 93.5 %) and accuracy (86.5 % and 81.0 %, respectively).</p> <p><strong>Conclusions: </strong>Real-world CXR diagnostic performance during the COVID-19 pandemic showed overall high sensitivity with higher specificity for more experienced radiologists. The increase in accuracy over time strengthens CXR role as a first line examination in suspected COVID-19 patients.</p>
Dataset related to article "RT-NET: real-time reconstruction of neural activity using high-density electroencephalography"
<p>Computation time for each of the 10 participants, related to head segmentation, leadfield matrix creation and spatial filter creation, respectively.</p>
Dataset related to article: "Therapist Driven Rehabilitation Protocol for Patients with Chronic Heart and Lung Diseases: A Real-Life Study"
<p>We provide the raw data used for the following article:</p> <ul> <li>Simonelli C, Vitacca M, Ambrosino N, Scalvini S, Rivadossi F, Saleri M, Fokom AG, Speltoni I, Ghirardi R, Paneroni M.<br> <em>Therapist Driven Rehabilitation Protocol for Patients with Chronic Heart and Lung Diseases: A Real-Life Study</em>.<br> "Int J Environ Res Public Health". 2020 Feb 5;17(3):1016. doi: 10.3390/ijerph17031016. PMID: 32033505; PMCID: PMC7037983.</li> </ul> <p><br> <strong>Abstract</strong><br> Therapist driven protocols may help to tailor rehabilitation programs to individual patients. We aimed to test the feasibility, safety, and clinical usefulness of a therapist driven protocol for rehabilitation including exercise training of patients with heart or lung diseases. An internal audit elaborated the Cardio-Respiratory Exercise Maugeri Algorithm (CREMA) based on: (a) standardized baseline assessments, (b) decision-making pathways, and (c) frequency/intensity/time/type (FITT) of prescription for each exercise. Outpatients (<em>n</em> = 620) with chronic heart disease (CHD), recent myocardial revascularization (REVASC), chronic airway (Obstructive), and restrictive lung (Restrictive) diseases underwent exercise training according to CREMA during 4 years. Peripheral muscle strengthening was the most prescribed exercise (83.6%), while arm endurance training was the least frequently (0.75%). Exercise prescription varied widely among the disease groups (interval training 19-47%, balance 35-49%, lower limb muscle training 6-15%). After training, REVASC patients were the best improvers in the 6 min walking distance (+48.7 (56.1) m), maximal inspiratory pressure (+9.6 (15.4) cmH<sub>2</sub>O), and daily steps (+1087.2 (3297.1) n/day). Quadriceps and biceps strength, maximal expiratory pressure, and balance improved in all groups, without significant differences. Minor side effects were observed in 11.2% of the patients. The CREMA therapist driven protocol was feasible, safe, and useful for prescribing tailored training programs. Exercise prescriptions and training response differed among diseases.</p>
Calibration of adaptive energy management strategies for fuel cell trucks using real-world driving scenarios
<p>Energy management strategies have a significant impact on the hydrogen economy of fuel cell trucks and the lifetime of battery and fuel cell systems. Usually, the strategy design and calibration involve a multi-objective optimization of performance indexes related to hydrogen consumption, fuel cell transients, battery thermal state, and battery charge control. This contribution presents the calibration of an energy management strategy that is adaptive to battery and ambient temperature. Indeed, fuel cell trucks face critical operating conditions due to high ambient temperatures or high loads on long uphill roads. However, the presented adaptive energy management strategy can effectively avoid thermal issues to preserve the battery life without hindering the hydrogen economy. The strategy calibration can be optimized using a simulation environment consisting of drivetrain components in AVL CRUISE M and vehicle control unit functions in MATLAB Simulink. Moreover, AVL CAMEO can systematically vary the adaptive strategy's curve parameters to find the best trade-off between the key performance indexes. The calibration considers real-world driving cycles of road freight vehicles, including measured speed, road elevation, and variable vehicle mass. The calibration is robust because the performance indexes are optimized over more than 9000 kilometers, covering an extensive range of real-world driving scenarios. Besides the benefits of optimal calibrations, this contribution also provides interesting insights into the energy and thermal management problem of fuel cell trucks.</p>
Dataset related to article "Real life long-term efficacy and safety of ixekizumab in moderate-to-severe psoriasis: A 192 weeks multicentric retrospective study-IL PSO (Italian landscape psoriasis)"
<p>This record contains raw data related to article “Real life long-term efficacy and safety of ixekizumab in moderate-to-severe psoriasis: A 192 weeks multicentric retrospective study-IL PSO (Italian landscape psoriasis)"</p> <p> </p> <p>Abstract:</p> <p>Psoriasis is one of the commonest inflammatory skin diseases determining a very high impact on patients' quality of life and daily activities and relationships. Several biologic therapies have been approved through the years for the treatment of moderate-to-severe plaque psoriasis, and efficacy and safety profile have been analyzed in clinical trials. Ixekizumab is an immunoglobulin G subclass 4 monoclonal antibody that selectively targets and binds IL-17A with high specificity and affinity. Inhibiting IL-17A activity, ixekizumab reduces and turns down levels of inflammation, resulting in the clinical improvement of the disease. Long-term efficacy and safety profile of ixekizumab have been investigated and reported in the UNCOVER trials, but in literature there are only few studies based on real life experience. We present the efficacy and safety profile of ixekizumab in a cohort of 779 patients affected by moderate-to-severe plaque psoriasis and treated with ixekizumab in 11 Italian dermatology hospitals, with a follow-up of care until 192 weeks.</p>
Dataset related to article "Real-life effectiveness of tildrakizumab in chronic plaque psoriasis: A 52-week multicentre retrospective study-IL PSO (Italian landscape psoriasis) "
<p>This record contains raw data related to article “Real-life effectiveness of tildrakizumab in chronic plaque psoriasis: A 52-week multicentre retrospective study-IL PSO (Italian landscape psoriasis)"</p> <p>Abstract</p> <p><strong>Background: </strong> Tildrakizumab is a humanized monoclonal antibody that binds selectively the p19 subunit of interleukin-23. It is approved for treatment of moderate-severe chronic plaque psoriasis.</p> <p><strong>Objectives: </strong> We conducted a 52-week retrospective study to assess the effectiveness and safety of tildrakizumab in a real-life setting.</p> <p><strong>Methods: </strong> Our retrospective study included 237 consecutive adults with moderate-to-severe plaque psoriasis, enrolled in 10 different Italian centres, treated with tildrakizumab up to Week 52. Patient characteristics, comorbidities, previous treatments and the PASI (Psoriasis Area and Severity Index) score at each visit (baseline, Week 16, Week 28 and Week 52) were retrieved from the electronic medical records. The percentages of patients achieving 75%, 90% and 100% (PASI 75, PASI 90 and PASI 100) improvement in PASI with respect to baseline PASI were registered.</p> <p><strong>Results: </strong> At Week 52, 90.91%, 73.55% and 58.68% of patients achieved a PASI reduction ≥75% (PASI 75), PASI 90 and PASI 100, respectively. An absolute PASI ≤ 2 was reached by 85.95% at Week 52. Compared with Phase 3 clinical trials, we observed similar rates of PASI 75/90 responses and higher percentages of patients achieving PASI 100. Patients who had not responded to previous biologic treatments and patients with cardio-metabolic comorbidities were significantly more likely to achieve PASI 100 at Week 28 and PASI 90 at Week 52. The higher body mass index did not interfere with the odds of reaching PASI 75/90/100 at each time point. No significant safety findings were recorded throughout the study, and none of the patients had to interrupt the treatment because of adverse events.</p> <p><strong>Conclusion: </strong> Our data suggest that the efficacy of tildrakizumab for plaque psoriasis in 'real-life' clinical practice is comparable with Phase 3 clinical trials with higher percentages of patients achieving complete skin clearance (PASI 100) at Weeks 16, 28 and 52.</p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.